Identifying Subgroups of YpN1 Breast Cancer Patients Who May Exempt from Axillary Lymph Node Dissection After Neoadjuvant Chemotherapy: Insights from a Large Cohort Study

Overview

Journal Breast Cancer

Specialty Oncology

Date 2024 Dec 27

PMID 39729291

Authors

Peinan Liu

Dandan Liu

Changying Zhao

Yumeng Wei

Xingyu Liu

Hanxiao Cui

Xuyan Zhao

Lidan Chang

Shuai Lin

Hao Wu

Xiaobin Ma

Huafeng Kang

Meng Wang

Affiliations

Soon will be listed here.

Abstract

Background: In patients with breast cancer staged ypN1 after neoadjuvant chemotherapy (NAC), there is limited evidence-based guidance regarding exemption from axillary lymph node dissection (ALND).

Methods: This study analyzed ypN1 breast cancer patients post-NAC from the Surveillance, Epidemiology, and End Results databases. Patients were categorized into the breast-conserving surgery (BCS) group and the total mastectomy (TM) group, and further divided by the number of positive lymph nodes (LNs). The effects of three axillary management strategies, ALND, sentinel lymph node biopsy combined with radiotherapy (SLNB + RT), and ALND + RT were compared. The overall survival (OS) and breast cancer-specific survival (BCSS) of all subgroups and their independent risk factors were analyzed. Independent prognostic factors selected from multivariate Cox analysis were utilized to create nomograms for predicting OS and BCSS.

Results: A total of 3641 patients were involved, with 1331 in the BCS group and 2310 in the TM group. In the TM group, patients with 3 residual positive LNs exhibited significant improvements in OS and BCSS when treated with ALND + RT. For patients with 1 or 2 residual positive LNs in the TM group and all BCS patients, no significant survival differences in survival outcomes were observed among the three axillary management methods. The accuracy of the nomograms was validated via calibration curves, receiver operating characteristic curves, and decision curve analysis curves.

Conclusion: For TM group patients with 3 residual positive LNs after NAC, ALND + RT is recommended. For other subgroups of ypN1 patients, SLNB + RT can be considered an alternative to ALND. The nomogram developed to predict OS and BCSS in ypN1 breast cancer patients demonstrated excellent predictive ability.

References

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6):546-53. DOI: 10.1056/NEJMoa012782. View

Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View

Land S, Kopec J, Julian T, Brown A, Anderson S, Krag D . Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010; 28(25):3929-36. PMC: 2940391. DOI: 10.1200/JCO.2010.28.2491. View

Giuliano A, Ballman K, McCall L, Beitsch P, Whitworth P, Blumencranz P . Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011.... Ann Surg. 2016; 264(3):413-20. PMC: 5070540. DOI: 10.1097/SLA.0000000000001863. View

Donker M, van Tienhoven G, Straver M, Meijnen P, van de Velde C, Mansel R . Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15(12):1303-10. PMC: 4291166. DOI: 10.1016/S1470-2045(14)70460-7. View

Tinterri C, Gentile D, Gatzemeier W, Sagona A, Barbieri E, Testori A . Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial. Ann Surg Oncol. 2022; 29(9):5732-5744. DOI: 10.1245/s10434-022-11866-w. View

Frei 3rd E . Clinical cancer research: an embattled species. Cancer. 1982; 50(10):1979-92. DOI: 10.1002/1097-0142(19821115)50:10<1979::aid-cncr2820501002>3.0.co;2-d. View

Shien T, Iwata H . Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020; 50(3):225-229. DOI: 10.1093/jjco/hyz213. View

10.

Rastogi P, Anderson S, Bear H, Geyer C, Kahlenberg M, Robidoux A . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26(5):778-85. DOI: 10.1200/JCO.2007.15.0235. View

11.

van der Hage J, van de Velde C, Julien J, Tubiana-Hulin M, Vandervelden C, Duchateau L . Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19(22):4224-37. DOI: 10.1200/JCO.2001.19.22.4224. View

12.

Heidinger M, Knauer M, Tausch C, Weber W . Tailored axillary surgery - A novel concept for clinically node positive breast cancer. Breast. 2023; 69:281-289. PMC: 10034500. DOI: 10.1016/j.breast.2023.03.005. View

13.

Kunkler I, Canney P, van Tienhoven G, Russell N . Elucidating the role of chest wall irradiation in 'intermediate-risk' breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008; 20(1):31-4. DOI: 10.1016/j.clon.2007.10.004. View

14.

Pilewskie M, Morrow M . Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review. JAMA Oncol. 2016; 3(4):549-555. PMC: 5580251. DOI: 10.1001/jamaoncol.2016.4163. View

15.

Barrio A, Montagna G, Mamtani A, Sevilimedu V, Edelweiss M, Capko D . Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event. JAMA Oncol. 2021; 7(12):1851-1855. PMC: 8498932. DOI: 10.1001/jamaoncol.2021.4394. View

16.

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G . Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013; 14(7):609-18. DOI: 10.1016/S1470-2045(13)70166-9. View

17.

Boileau J, Poirier B, Basik M, Holloway C, Gaboury L, Sideris L . Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2014; 33(3):258-64. DOI: 10.1200/JCO.2014.55.7827. View

18.

Classe J, Loaec C, Gimbergues P, Alran S, Tunon de Lara C, Dupre P . Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2018; 173(2):343-352. DOI: 10.1007/s10549-018-5004-7. View

19.

Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P . Axillary surgery in breast cancer: An updated historical perspective. Semin Oncol. 2020; 47(6):341-352. DOI: 10.1053/j.seminoncol.2020.09.001. View

20.

Beck A, Morrow M . Axillary lymph node dissection: Dead or still alive?. Breast. 2023; 69:469-475. PMC: 10300611. DOI: 10.1016/j.breast.2023.01.009. View

21.

Gerber B, Heintze K, Stubert J, Dieterich M, Hartmann S, Stachs A . Axillary lymph node dissection in early-stage invasive breast cancer: is it still standard today?. Breast Cancer Res Treat. 2011; 128(3):613-24. DOI: 10.1007/s10549-011-1532-0. View